Is Avalo Therapeutics Inc (AVTX) overvalued? · P/E 0.0, rev $441.0K
Avalo Therapeutics Inc (AVTX) is a biotechnology company listed on US.
This page asks whether Avalo Therapeutics Inc (AVTX) looks expensive on cached numbers — not a short thesis.
Latest reported AVTX revenue for 2024-12-31 was $441.0K. Net income was -$35.1M. Revenue was down 77.1% from 2023-12-31 to 2024-12-31. AVTX currently screens at market cap $51.5M and trailing P/E 0.0.
AVTX currently screens at market cap $51.5M and trailing P/E 0.0. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next AVTX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the AVTX stock page for the full model, not this heading.
Not investment advice.